Amphastar Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Amphastar Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).
Amphastar Pharmaceuticals: 21 sponsored US clinical trials, 1 recruiting.
Amphastar Pharmaceuticals sponsors 21 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 15 completed. 8 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Asthma, with 4 trials.
Top-decile sponsor footprint
Amphastar Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
15 of 20 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
21 total, page 1 of 1
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers
NCT07560150
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers
NCT05539872
Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals
NCT04207840
Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers
NCT02271334
Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation
NCT02210806
Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults
NCT01737892
Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma
NCT01737905
Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)
NCT01689363
Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation
NCT01581177
Safety Study in Adolescent and Adult Patients With Asthma
NCT01476904
Evaluation of Efficacy and Safety of E004 in Children With Asthma
NCT01460511
Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients
NCT01357642
Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS
NCT01255709
Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics
NCT01188577
Dose-Ranging Study of A006 DPI, in Adult Asthma Patients
NCT01174732
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
NCT01189396
Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers
NCT01143051
Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.
NCT01025648
4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma
NCT00634517
Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction
NCT00634829
Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients
NCT00635505
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 9 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Amphastar Pharmaceuticals pipeline
1 recruiting of 21 indexed (5% open); 15 completed (71%).
Phase mix: 8 late (III/IV) vs 13 early (I/II) (early-phase heavy).
Top condition: Asthma (4 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Amphastar Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 21 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
Amphastar Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 21 trials (± recruiting share)
- AEterna Zentaris · 21 trials · 0% recruiting
- Apellis Pharmaceuticals · 21 trials · 10% recruiting
- Array Biopharma, now a wholly owned subsidiary of Pfizer · 21 trials · 0% recruiting
- Basilea Pharmaceutica · 21 trials · 14% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Cook County Health · 5% recruiting · 21 trials
- David Grant U.S. Air Force Medical Center · 5% recruiting · 21 trials
- Duquesne University · 5% recruiting · 21 trials
- Legacy Health System · 5% recruiting · 21 trials
Related
What to do with this Amphastar Pharmaceuticals page
21 registered trials is a research-attention snapshot, not an endorsement of Amphastar Pharmaceuticals or any single study.
- 1 of Amphastar Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Asthma is the condition Amphastar Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Asthma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Amphastar Pharmaceuticals pipeline card: 21 registered trials from official public datasets.Report a data error.